UBS AM is a patent business unit of UBS Asset Management Americas LLC, lessening its holdings in shares of HCA Healthcare, Inc. by 0.9% in the first quarter, as recorded in the company’s current filing with the SEC. The institutional investor is the owner of 1,659,647 shares of the company’s stock after the sale of 15,813 shares during the quarter. The UBS AM, a patent business unit of UBS Asset Management Americas LLC, owned up to 0.69% of HCA Healthcare worth $573,491,000, mentioned in the recent filing with the SEC.
The large investors increasing numbers have purchased and sold shares of the business. Avantax Advisory Services Inc. accelerated its holdings in shares of HCA Healthcare by 0.4% in the first quarter. Following, Avantax Advisory Services Inc. is now the owner of 8,077 shares, with the company’s stock value at $2,791,000 after purchasing an additional 32 shares in the last quarter. The Horizon Investments LLC elevated its presence in HCA Healthcare by 1.1% in the first quarter, owning 3,175 shares of the company’s stock costing $1,097,000 after acquiring 33 shares during the last quarter. The Catalyst Financial Partners LLC leveled up its position in HCA Healthcare by 4.3% in the first quarter and currently owns 872 shares of the company’s stock, costing $301,000 after acquiring 36 shares during the last quarter.
RWA Wealth Partners LLC elevated its position in shares of HCA Healthcare by 2.0% in the first quarter, owning 1,904 shares of the company’s stock worth $658,000 after purchasing 37 shares in the last quarter. Lastly, Moors and Cabot Inc. increased its holdings in HCA Healthcare by 4.8% during the first quarter, owning 858 shares of the company’s stock valued at $297,000 after buying 39 shares in the last quarter. A total of 62.73% of the stock is owned by institutional investors.
The EVP Michael S. Cuffe sold out 3,836 shares of the company’s stock in a transaction recorded in 8th September on Monday. The stock was sold at an estimated price of $418.84 for a total cost of $1,606,670.24. Reading the completion of the transaction, the executive vice president gained 31,503 shares of the company’s stock, worth $13,194,716.52. This shows a 10.85% decline in their ownership of the stock. A total of 1.30 of % stock is owned by the company insiders.
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
